Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refract...
Leadership
Michael A. Metzger M.B.A.
CEO & Director
Keith Alan Goldan CPA
CFO, Treasurer & Principal Accounting Officer
Luke J. Albrecht J.D.
Senior VP, General Counsel & Secretary
Steven Closter
Chief Commercial Officer
Nicholas A.J. Botwood B.Sc., MBBS
Head of Research & Development and Chief Medical Officer
Peter Ordentlich B.Sc., Ph.D.Founder
Co-Founder & Chief Scientific Officer
Richard A. Heyman Ph.D.Founder
Co-Founder
Ronald M. Evans Ph.D.Founder
Co-Founder, Advisor and Chair of Scientific Advisory Board
Michael Downes Ph.D.Founder
Co-Founder
Sharon Klahre
Vice President of Investor Relations & Communications
